Lilly’s triple agonist still leads among late-stage obesity assets
礼来三重激动剂仍领跑减重药物后期管线

Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They had better hope they’re right, because if it is a competition, Eli Lilly is winning.
许多肥胖症药物的研发者常说，他们追求的并不是最快、最强的减重效果。但他们最好真是如此认为，因为如果这是一场比拼，那当前的赢家就是礼来。